Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC

BLA FilingOpamtistomigPositive

AI Analysis

Summary

Nanjing Leads Biolabs announced Priority Review designation for its PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) as monotherapy for extrapulmonary neuroendocrine carcinoma, accelerating the regulatory pathway and commercialization timeline.

Outcome Details

Priority Review granted for PD-L1/4-1BB bispecific antibody as monotherapy

Importance:7/10

Sentiment:

0.80

Priority ReviewBLA FilingBispecific AntibodyImmunotherapyRare Disease

Related Companies

$9887.HK

Read the original article

Published by PR Newswire Pharma on July 10, 2026 8:53 AM

Read Original